ST. LOUIS, Oct. 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS - ) announced today that it has been added to the Russell 3000® and Russell 2000® Indices, as of October 1, 2004.

"As a company that has recently completed an initial public offering, we're pleased to be included in the Russell Indices," commented Bevil J. Hogg, President and Chief Executive Officer of Stereotaxis. "We expect that our inclusion in these prestigious indices will further raise Stereotaxis' visibility within the financial community. We continue to execute our business strategy in order to grow our company and realize our full potential."

The Russell 3000® Index offers investors access to the broad U.S. equity universe and measures the performance of the 3,000 largest U.S. companies based on total market capitalization, which represents approximately 98 percent of the investable U.S. equity market. The Russell 2000® Index offers investors access to the small-cap segment of the U.S. equity universe and includes the smallest 2000 securities in the Russell 3000.

The Russell family of 21 U.S. indices is designed to be a comprehensive representation of the investable U.S. equity market. These indices are value- weighted and include only common stocks belonging to corporations domiciled in the United States and its territories.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire. All core components of the Stereotaxis System have received regulatory clearance in the U.S. and Europe.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward- looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Contacts:

     Stereotaxis, Inc.                       Euro RSCG Life NRP
     314-615-6957                            212-845-4253
     Jim Stolze, Chief Financial Officer     Ernie Knewitz (media)
     jstolze@stereotaxis.com                 ernie.knewitz@eurorscg.com

                                             212-845-4269
                                             Brian Ritchie (investors)
                                             brian.ritchie@eurorscg.com